top of page

C3 Podcast No. 20: Survey of CBG Users

Updated: Dec 14, 2022

In No. 20 of the Cannabis Commerce + Chemistry Podcast, host Curt Robbins from Higher Learning LV and co-hosts John Bailey from the Mindset Genesis in Las Vegas and Dena Putnam from Leafwize Naturals in Orange County, California discuss an October 2022 research study about the cannabinoid cannabigerol, or CBG.


This fast-paced roundtable teaches listeners about the potential health and wellness benefits of CBG and popular commercial products that offer this phytomolecule.

Bailey, Putnam, and Robbins discuss the ways in which CBG may help those who consume it, including reductions in anxiety, depression, and chronic pain and potential improvements for sleep disorders. They discuss the results and industry ramifications of the study, including how the majority of those surveyed considered their use of CBG to be beneficial, with minimal side effects (unlike THC). The group compares and contrasts CBG with cannabidiol, or CBD and tetrahydrocannabinol, or THC.


🎧 Listen to C3 Podcast >> Survey of CBG Users


This weekly 30-minute podcast is targeted at cannabis and hemp industry professionals and is strategically free of profanity and crude dialog. This audio session was edited for length and clarity.


To better understand how patients and consumers are using the cannabinoid CBG to treat a variety of condition—including sleep disorders, anxiety, depression, and chronic pain—listen now at Higher Learning LV, on Apple Podcasts or Spotify, and most other major podcasting platforms (including Amazon Music, Anchor, Google Podcasts, iHeart Radio, Pandora, and Stitcher).





Survey of CBG Patients (October 2022)


An October 2022 study entitled "Survey of Patients Employing Cannabigerol-Predominant Cannabis Preparations: Perceived Medical Effects, Adverse Events, and Withdrawal Symptoms" that was published in the journal Cannabis and Cannabinoid Research explored the potential medicinal efficacy of the cannabis- and hemp-derived cannabinoid cannabigerol (CBG).

The study's authors—who included cannabis research pioneer Dr. Ethan Russo—stated that the purpose of their scientific investigation was to explore "reasons for use and self-reported therapeutic effects in CBG-predominant cannabis users." The researchers observed CBG usage patterns and looked for potential adverse effects, including withdrawal symptoms (spoiler: very found were found).


Study Conclusions

"Most of the participants (51%) reported use of CBG-predominant products solely for medical purposes (36% reported use for medical and recreational purposes; 6% reported recreational use only).


The most common conditions the study subjects reported using CBG to treat were:

  1. Anxiety (51%)

  2. Chronic pain (41%)

  3. Depression (33%)

  4. Insomnia/disturbed sleep (31%)

View the original study.


Like what you just read? Check out our new Cannabis for Cancer Hub that features links to all of our articles about marijuana for cancer.

36 views0 comments

Recent Posts

See All
bottom of page